Evaluation of the Efficacy & Safety of VX-864 in Subjects With the PiZZ

Updated 06/21/2024

Status Completed

Clinical Trial Summary

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04474197
Study type	Interventional
Source	Vertex Pharmaceuticals Incorporated
Contact
Status	Completed
Phase	Phase 2
Start date	July 24, 2020
Completion date	May 4, 2021

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02282527` - A Study to Assess Safety and PK of Liquid Alpha1-Proteinase Inhibitor (Human) in Treating Alpha1-Antitrypsin Deficiency	Phase 2/Phase 3
	Terminated	`NCT02722304` - Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency	Phase 3
	Withdrawn	`NCT04440488` - ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study	Phase 4
	Completed	`NCT02525861` - GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study	Phase 3
	Recruiting	`NCT05677971` - Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein	Phase 3
	Recruiting	`NCT06165341` - Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)	Phase 3
	Completed	`NCT00157092` - Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency	Phase 1/Phase 2
	Terminated	`NCT00313144` - Aralast alpha1-proteinase Inhibitor Surveillance Study	Phase 4
	Completed	`NCT01651351` - GLASSIA Infusion Rate Study	Phase 4
	Completed	`NCT02870348` - Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)	Phase 1/Phase 2
	Completed	`NCT02870309` - Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency	Phase 1/Phase 2
	Completed	`NCT00161707` - Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency	Phase 1/Phase 2
	Withdrawn	`NCT05466747` - A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema	Phase 4
	Enrolling by invitation	`NCT05899673` - An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease	Phase 3
	Recruiting	`NCT04722887` - A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency	Phase 1/Phase 2
	Recruiting	`NCT02929940` - Liver Disease in Patients With alpha1-antitrypsin Deficiency	N/A